Genfit Ends Phase 3 Trial of NASH Drug Elanfibranor After Finding No Benefit By Sam | July 22, 2020 Genfit said it will now focus on developing the drug for the treatment of primary biliary cholangitis, a chronic liver disease. Source: Devices & Diagnostics Letter Posted in Devices & Diagnostics Letter